Radiopharmaceutical developer Draxis Health reported that the Food and Drug Administration has approved its DraxImage division's new, larger format of its HiCon kit for the preparation of sodium iodide I-131 capsules and oral solution.
The new format was developed at the request of the firm's high-volume radiopharmacy customers in the U.S. and will serve to round out the existing line of DraxImage radioactive iodine I-131 products, according to the Mississauga, Ontario-based firm.
In a further strategic move to focus production activities, DraxImage has initiated a process that will see it discontinue the manufacture and sale of implantable brachytherapy seeds by December 15 this year as part of an orderly exit from the brachytherapy market, the company said.
By AuntMinnie.com staff writersNovember 22, 2005
Related Reading
Draxis Health lowers expectations, November 21, 2005
Temporary shutdown hurts Draxis Health’s Q3, November 3, 2005
Draxis taps Brazier as COO, October 4, 2005
Draxis posts Q2 rise, August 11, 2005
Draxis joins Nasdaq biotech index, May 16, 2005
Copyright © 2005 AuntMinnie.com
